Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment—A Case Report
Katarina Čular, Dora Tomek Hamzić, Ljiljana Smiljanić Tomičević, Daška Štulhofer Buzina, Mirna Bradamante, Luka Simetić, Ivan Bilić, Borislav Belev · 2026
Read Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment—A Case Report by Katarina Čular, Dora Tomek Hamzić, Ljiljana Smiljanić Tomičević, Daška Štulhofer Buzina, Mirna Bradamante, Luka Simetić, Ivan Bilić, Borislav Belev (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13298184.txt.
Description
A bile duct cancer drug set off a rare and deadly skin disease in a case told by Katarina Čular and her team in 2026. A 43-year-old woman with spread liver bile duct cancer took pemigatinib, a drug that blocks the FGFR2 growth switch. Seven months in, she broke out in calciphylaxis, a grim state where small blood vessels crust with calcium and skin dies.
A skin biopsy proved the cause. The team stopped the drug and gave germ-fighting drugs and full support care. She still worsened and died of sepsis as the cancer grew too. The team urges doctors who use this drug class to watch the skin with care. Early spotting and a fast stop may be the one chance to help.
Catalog record
| CREATOR | Katarina Čular, Dora Tomek Hamzić, Ljiljana Smiljanić Tomičević, Daška Štulhofer Buzina, Mirna Bradamante, Luka Simetić, Ivan Bilić, Borislav Belev |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15059 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |